Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary independently developed desulimide antibiotic HLX14 (i.e. recombinant anti-RANKL whole human monoclonal antibody injection) drug registration application with a size of 120 mg (1.7 ml) /bottle was accepted by the State Drug Administration. The indications declared this time are all the indications for which the reference drug Agave® (English product name: XGEVA®) has been approved for marketing in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.